Pursuant to the provisions of regulation 30 of the Listing Regulations, Zydus Lifesciences has informed that the Company and Zydus Pharmaceuticals USA, Inc., USA, a wholly owned subsidiary, (together referred to as ‘Zydus’), have entered into a Settlement Agreement with Astellas in relation to Astellas’ Myrbetriq® (generic name: Mirabegron). This development is in continuation of its earlier intimation dated April 17, 2025, regarding the US patent litigation with Astellas. Under the terms of the Settlement Agreement: 1. Zydus shall pay Astellas an aggregate amount of USD 120 million. 2. Zydus shall additionally pay a prepaid per unit licensing fee on units of Zydus’ generic Mirabegron sold in the US from the date of Settlement Agreement till September 2027. Other terms and conditions of the Settlement Agreement remain confidential. This Settlement Agreement concludes all litigations between Astellas and the two companies relating to Myrbetriq® and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the US.

The above information is a part of company’s filings submitted to BSE.